Evaluation of Novel Urinary Renal Biomarkers with a Cisplatin Model of Kidney Injury: Effects of Collection Period

Toxicologic Pathology

Volumn 40, Issue 3, 2012, Pages 534-540

  Pinches, Mark D ^a   Betts, Catherine J ^a   Bickerton, Susan J ^a   Beattie, Laura ^a   Burdett, Lisa D ^a   Thomas, Helen T ^a   Derbyshire, Nicola A ^a   Moores, Michele ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

biomarkers; clinical pathology; preclinical safety assessment risk management; renal; safety assessment; toxicologic pathology

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; ALBUMIN; CREATININE; GLUCOSE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA; KIDNEY INJURY MOLECULE 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; PROTEIN; RENAL PAPILLARY ANTIGEN 1; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CYTOCHEMISTRY; DISEASE MODEL; FEMALE; KIDNEY DISEASE; MALE; METABOLISM; METHODOLOGY; RAT; REFERENCE VALUE; URINE; WISTAR RAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG URINE LEVEL; HISTOPATHOLOGY; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RELATIVE DENSITY; SEX DIFFERENCE; URINALYSIS; URINARY EXCRETION; URINE VOLUME;

ANIMALS; BIOLOGICAL MARKERS; CISPLATIN; DISEASE MODELS, ANIMAL; FEMALE; HISTOCYTOCHEMISTRY; KIDNEY DISEASES; MALE; RATS; RATS, WISTAR; REFERENCE VALUES; RESEARCH DESIGN;

EID: 84867451389     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311432437     Document Type: Review

References (28)

1. Altman D. G. Bland J. M. (1987). Measurement in medicine: The analysis of method comparison studies. The Statistician 32, 307–17.
2. Ferguson M. A. Vaidya V. S. Bonventre J. V. (2008). Biomarkers of nephrotoxic acute kidney injury. Toxicology 245(3), 182–93.
3. Fleiss J. L. (1981). Statistical Methods for Rates and Proportions. 2nd ed. J Wiley and Sons: New Jersey, US.
4. Fraser C. G. (2001). Biological Variation: From Principles to Practice. AACC Press, Washington, DC.
5. Garrett M. D. Workman P. (1999). Discovering novel chemotherapy drugs for the third millennium. Eur J Cancer 35, 2010–30.
6. Goodsaid F. M. Blank M. Dieterle F. (2009). Novel biomarkers of acute kidney toxicity. Clin Pharmacol Ther 86, 490–6.
7. Goodsaid F. Frueh F. (2007). Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J 9, E105–8.
8. Goodsaid F. M. Frueh F. W. Mattes W. (2008). Strategic paths for biomarker qualification. Toxicology 245, 219–23.
9. Han W. K. Bailly V. Abichandavi R. (2002). Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 62, 237–44.
10. Kinter S. H. (2005). Assessing renal effects of toxicants in vivo. In Toxicology of the Kidney (Lash E. B., ed.), 3rd ed. CRC Press, Boca Raton, FL.
11. Kola I. Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3, 711–716.
12. Landis J. R. Koch G. G. (1977). The measurement of observer agreement for categorical data. Biometrics 33(1), 159–74.
13. Lesco L. K. Atkinson A. J., Jr (2001). Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Ann Rev Pharmacol Toxicol 41, 347–66.
14. Maruhn D. Strozyk K. Gielow L. Bock K. D. (1977). Diurnal variations of urinary enzyme excretion. Clin Chim Acta 75, 427–33.
15. Ozer J. S. Dieterle F. Troth S. (2010). A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nature Biotech 28, 486–94.
16. Pinches M. D. Betts C. J. Bickerton S. J. Beattie L. Burdett L. D. Thomas H. T. Derbyshire N. A. Moores M. Price S. A. (2012a). Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: Methodology and reference ranges. Toxicol Pathol 40(3), 531–39.
17. Pinches M. D. Betts C. J. Bickerton S. J. Burdett L. D. Thomas H. T. Derbyshire N. A. Jones H. B. Moores M. (2012b). Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: Gender and dosage differences. Toxicol Pathol 40(3), 512–23.
18. Pons M. Forpomes O. Espagnet S. (1996). Circadian changes in physiological urinary excretion of glycosaminoglycans in healthy rats. Pathol Biol (Paris) 44, 189–95.
19. Racusen L. Kasgarian M. (2007). Ischemic and toxic acute tubular injury and other ischemic renal injury. In Hepinstall’s Pathology of the Kidney. Williams Lipincott Williams : Philidelphia, US.
20. Roelfsema F. van der Heidea D. Smeenka D. (1980). Circadian rhythms of urinary electrolyte excretion in freely moving rats. Life Sci 27, 2303–9.
21. Rouse R. Zhang J. Stewart S R. Rosenzweig B A. Espandiari P. Sadrieh N K. (2011). Comparative profile of commercially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats. Kidney International 79, 1186–1197.
22. Scales W. E. Kluger M. J. (20). Effect of antipyretic drugs on circadian rhythm in body temperature of rats. Am J Physiol Regulatory Integrative Comp Physiol 253, R306–13.
23. Shepherd D. S. (1986). Feeding patterns and operant responding by wild and domesticated rats in self-maintenance conditions. Behav Brain Res 19, 83–7.
24. Sheskin D. J. (2003). Handbook of Parametric and Nonparametric Statistical Procedures. 3rd ed. Chapman and Hall/CRC: Florida, US.
25. Star R. A. (1998). Treatment of acute renal failure. Kidney Int 54, 1817–31.
26. Vaidya V. S. Ferguson M. A. Bonventre J. V. (2008). Biomarkers of acute kidney injury. Annual Reviews of Pharmacology and Toxicology 48, 463–93.
27. Yu Y. Jin H. Holder D. (2010). Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nature Biotech 28, 470–7.
28. Zhou Y. Vaidya V. S. Brown R. P. (2008). Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci 101, 159–170.